-

Shareholder Alert: Robbins LLP Announces Pilgrim's Pride Corporation (PPC) Accused of Misleading Shareholders

SAN DIEGO & GREELEY, Colo.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Pilgrim's Pride Corporation (NASDAQ: PPC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 9, 2017 and June 3, 2020. Pilgrim's Pride produces, processes, markets, and distributes fresh, frozen, and value-added chicken and pork products.

If you suffered a loss as a result of Pilgrim's Pride's misconduct, click here.

Pilgrim's Pride Corporation (PPC) Accused of Misleading Shareholders

According to the complaint, throughout the relevant period, in each of its annual reports Pilgrim's Pride touted that the Company's business strategies, including its broad product portfolio and its disciplined capital allocation, had given Pilgrim's Pride competitive strengths, advantages and market positioning that accelerated the Company's growth. Each of these annual reports attested that the report did not contain "any untrue statement of material fact or omit to state a material fact." However, Pilgrim's Pride failed to disclose that its business strategies also included an illegal antitrust conspiracy to fix prices and rig bids from as early as 2012. Its true business practices were revealed on June 3, 2020, when the U.S. Department of Justice announced that a federal grand jury in the District of Colorado found four chicken industry executives, including Pilgrim's Pride current CEO and two former Vice Presidents, guilty of criminal antitrust violations. The indictment alleged these industry executives “participat[ed] in a continuing network of Suppliers and coconspirators… to suppress and eliminate competition through rigging bids and fixing prices and price-related terms for broiler chicken products sold in the United States.” On this news, Pilgrim's Pride share price fell 12.4% to close at $18.29 per share. The stock continues to decline.

If you purchased Pilgrim's Pride Corporation (PPC) securities between February 9, 2017 and June 3, 2020, you have until September 4, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action on behalf of Pilgrim's Pride settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:PPC

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom